
Anti-CTLA-4 prior to anti-PD-1
No anti-CTLA-4 prior to anti-PD-1
A
HR 0.88; 95% CI 0.61-1.27; p=0.49
No previous RT
Previous RT
Progression-free survival
Time since start of anti-PD-1 therapy (months)
No. at risk:
122 36 16 8 0
70 9 0
B
HR 0.91; 95% CI 0.47-1.75; p=0.78
No previous RT
Previous RT
Progression-free survival
Time since start of anti-PD-1 therapy (months)
No. at risk:
32 12 10 0
15 6 4 0
C
HR 0.78; 95% CI 0.44-1.38; p=0.39
No previous RT
Previous RT
Overall survival
Time since start of anti-PD-1 therapy (months)
No. at risk:
122 58 32 20 6 3 2 0
70 26 0
D
HR 0.36; 95% CI 0.08-1.57; p=0.17
No previous RT
Previous RT
Overall survival
Time since start of anti-PD-1 therapy (months)
No. at risk:
32 26 5 0
15 11 3 0